GET DAILY SIGNALSBeam Therapeutics (BEAM) Climbs +19% on Promising Base-Editing Data
Key Takeaways
- Beam Therapeutics (BEAM) advanced roughly 19% over the last 30 days, from about $24.52 to approximately $29.20 per share.
- The bulk of the move arrived in a single session: shares jumped 15.6% on October 28, 2026, after the company released initial Phase 1/2 data for its BEAM-301 program in glycogen storage disease type Ia (GSDIa).
- BEAM-301 demonstrated dose-dependent improvements in fasting tolerance, with two patients in the 40 mg cohort reaching the trial's 15-hour fasting limit and eliminating cornstarch supplementation.
- Analyst reaction was broadly positive, with H.C. Wainwright reiterating a Buy rating and an $80 price target and Citi reiterating Buy with a $68 target.
- Over the last quarter, BEAM is up about 12% but has been highly volatile, peaking near $31 in late August before sliding to roughly $23 in mid-September.
- A broader FDA push toward faster regulatory pathways for gene-editing medicines also lifted the gene-editing sector as a whole.
- For additional detail, explore Beam's Price Targets, Earnings, and Forecast pages.
- Investors can also review Trending AI Robots for AI-driven trading strategies across thousands of tickers.
Beam Therapeutics and Its Focus on Precision Gene Editing
Beam Therapeutics is a Cambridge, Massachusetts-based biotechnology company developing precision genetic medicines using base editing, a CRISPR-derived technology that makes precise single-letter changes to DNA without cutting both strands. The company applies this platform across hematology and liver-targeted genetic diseases, with lead programs including BEAM-301 for glycogen storage disease type Ia, BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-304 for phenylketonuria, alongside its ESCAPE non-genotoxic conditioning approach in sickle cell disease.
As a clinical-stage company, BEAM generates limited collaboration revenue and remains unprofitable, which makes its share price highly sensitive to clinical data readouts, regulatory developments, and funding considerations. Investors follow the stock primarily for its platform's potential to treat diseases with significant unmet need rather than for near-term earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, BEAM shares rose from a closing price of $24.52 on September 29, 2026, to approximately $29.20, a gain of about 19%. Most of that appreciation was concentrated in a single trading day, when the stock surged 15.6% on October 28 to close at $28.78 on sharply elevated volume.
The quarterly picture is more nuanced. Measured from late July, when shares traded around $26, BEAM is up roughly 12% over the trailing three months. However, the stock followed a volatile path: it climbed to a local peak near $31 in late August, retreated to about $23 by mid-September, and then rebounded through October as investors positioned ahead of the BEAM-301 readout. Even after the recent advance, the shares remain below their 52-week high of $38.26.
The Main Catalyst Behind the Recent Advance
The primary catalyst was clinical. On October 27, 2026, Beam reported initial data from its Phase 1/2 trial of BEAM-301, an in-vivo base-editing therapy designed to correct the R83C mutation underlying GSDIa, at the European Society of Gene and Cell Therapy (ESGCT) congress. The data showed dose-dependent gains in fasting tolerance: in the 40 mg cohort, two of three patients reached the 15-hour protocol-defined fasting maximum and no longer required starch supplementation, while the 20 mg cohort showed more modest improvement. The company also indicated plans to enroll a higher 60 mg cohort and to engage the FDA on a potential approval pathway.
The market reaction was immediate and decisive, with the stock closing 15.6% higher the following session. Analyst commentary reinforced the move. H.C. Wainwright reiterated a Buy rating with an $80 price target, Citi reiterated Buy at $68, and Evercore ISI maintained Buy at $45. Broader regulatory sentiment also provided a tailwind, as the FDA signaled faster routes for gene-editing therapies, lifting peers such as Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and CRISPR Therapeutics (CRSP).
Quarterly Trends and the Stock's Characteristic Volatility
The broader three-month trend reflects the stock's characteristic volatility around binary catalysts. Shares strengthened through August as the gene-editing sector benefited from improved risk appetite and anticipation of pipeline progress, reaching roughly $31. The stock then gave back those gains through mid-September, retreating to the $23 range amid a broader pullback and limited news flow.
The October BEAM-301 readout reversed that downtrend and re-centered the narrative on Beam's liver-targeted base-editing platform. The quarter's net result is a double-digit gain, but the path there underscores that Beam remains an early-stage, data-driven story in which a single readout or regulatory signal can move the stock substantially in either direction.
What to Watch Next for BEAM Stock
Several factors will shape BEAM's trajectory going forward. First, Beam's next quarterly earnings report is a key event, with the company expected to remain loss-making while investors assess its cash runway and operating expense trends. Second, the company's planned FDA engagement on a potential regulatory path for BEAM-301 will be closely watched, along with additional data from the higher 60 mg dose cohort. Third, further readouts across BEAM-302 and BEAM-304 will inform the durability of the platform thesis. Finally, broader sector sentiment, regulatory policy shifts toward gene editing, and financing conditions for clinical-stage biotechnology companies will continue to influence the stock, which remains highly sensitive to news flow.
Using AI Tools for Biotech Research
In my own workflow, I often turn to Tickeron’s Trending AI Robots to scan for systematic strategies that have shown consistency across volatile names in the gene-editing space. The page surfaces top-performing bots from a much larger universe, allowing me to cross-check ideas without replacing fundamental analysis. It serves as a practical discovery tool when evaluating how automated approaches might complement a position in a stock like this.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BEAM sees its Stochastic Oscillator climbs out of oversold territory
On October 20, 2026, the Stochastic Oscillator for BEAM moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 54 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BEAM as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for BEAM just turned positive on September 29, 2026. Looking at past instances where BEAM's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.
BEAM moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +20.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 197 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
BEAM broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BEAM entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.791) is normal, around the industry mean (3.151). P/E Ratio (-41.797) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which develops and commercializes DNA base editing technologies for the treatment of human disease.
Industry Biotechnology
Advertisement